SCHEMBL112702

SCHEMBL112702

CSc1nc(Cl)cc(Cc2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
ALDH1A1 P00352 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.42
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PPARG P37231 2/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
BRD4 O60885 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9323212 0.82 POLB (0.49) POLBALDH1A1MEN1KMT2AHSP90AA1
SCHEMBL112762 0.82 NPC1 (0.50) POLBMEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL10845926 0.78 POLB (0.49) POLBALDH1A1MEN1KMT2AHSP90AA1
SCHEMBL604508 0.77 ALDH1A1 (0.50) POLBALDH1A1MEN1KMT2AHSP90AB1
SCHEMBL27765197 0.77 HPGD (0.48) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL2462899 0.77 HTT (0.47) POLBALDH1A1MEN1KMT2AHSP90AA1
SCHEMBL3404366 0.77 ALDH1A1 (0.53) POLBALDH1A1MEN1KMT2AHSP90AB1
SCHEMBL1271857 0.76 KMT2A (0.63) POLBALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL26961001 0.76 KMT2A (0.39) POLBMEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL5475245 0.76 L3MBTL1 (0.51) POLBALDH1A1MEN1KMT2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK POLB 397/4885ALDH1A1 1469/4885MEN1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.